Intravenous Iron Dextran as a Component of Anemia Management in Chronic Kidney Disease: A Report of Safety and Efficacy

Objective. We aimed to demonstrate safety and efficacy of intravenous (IV) low molecular weight iron dextran (LMWID) during treatment of anemic stage 3 and 4 chronic kidney disease (CKD) patients. Methods. Efficacy data was obtained by retrospective chart review of 150 consecutively enrolled patient...

Full description

Saved in:
Bibliographic Details
Main Authors: Lenar Yessayan, Ankur Sandhu, Anatole Besarab, Alexy Yessayan, Stan Frinak, Gerard Zasuwa, Jerry Yee
Format: Article
Language:English
Published: Wiley 2013-01-01
Series:International Journal of Nephrology
Online Access:http://dx.doi.org/10.1155/2013/703038
Tags: Add Tag
No Tags, Be the first to tag this record!